This open-label, phase 2 randomized clinical trial assesses whether maintenance therapy with single-agent panitumumab was noninferior to panitumumab plus combined fluorouracil and leucovorin calcium among patients with RAS wild-type metastatic colorectal cancer.
This phase 2 randomized clinical trial assesses whether pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone enhances tumor response in patients with metastatic non–small cell lung cancer.
This phase 2 single-arm study evaluates outcomes following pembrolizumab treatment after locally ablative therapy in patients with oligometastatic non–small cell lung cancer.
This cohort study investigates the association of prediagnostic serum immune markers with the subsequent diagnosis of stable monoclonal gammopathy of undetermined significance vs progression to multiple myeloma.
This secondary analysis of the Stockholm Tamoxifen (STO-3) clinical trial, which was conducted from 1976 to 1990, assessed the long-term survival associated with tamoxifen therapy in postmenopausal patients with luminal A or B breast cancer tumor subtypes.
This cohort study evaluates the feasibility, risks, and advantages of resuming immune checkpoint inhibitor therapy in patients with cancer who experienced severe immune-related adverse events.
This cohort study uses data from the Southern Community Cohort Study to evaluate whether race-specific adjustment of pack-year criteria in the US Preventive Services Task Force (USPSTF) lung cancer screening guidelines is associated with more equitable screening for African American smokers at high risk for lung cancer.
This review of data from 75 families with a CDH1 pathologic variant compares estimates of the lifetime risk of gastric cancer in the families found to have a CDH1 pathologic variant through clinical ascertainment with those ascertained through multigene panel testing.
This open-label, nonrandomized, phase 1 study assesses the safety of pembrolizumab in patients with HIV and advanced cancer.
This population-based study estimates earnings lost owing to death from cancer in the United States nationally and by state.
This database study compared cancer-specific mortality in HIV-infected vs HIV-uninfected elderly patients after adjusting data for receipt of specific cancer treatments.
This review of novel oncology drugs approved by the US Food and Drug Administration examines the use of surrogate end points for overall survival, evaluates the use of patient-reported outcomes in trials supporting approvals, and seeks to determine whether drugs initially approved without evidence of overall survival or patient-reported outcome benefits demonstrate improvements in either measure postapproval.
This database study analyzes the association between hospital affiliation with top-ranked cancer hospitals and surgical safety at affiliate hospitals.
This study uses whole-genome sequencing to examine whether survivors of childhood lymphoma who are carriers of BRCA2 gene mutation have a greater likelihood of developing adult-onset cancers.
This review examines the main toxic effects of phosphatidylinositol 3-kinase inhibitors and recommends approaches to identification and management of such toxic effects.
A woman in her 80s presented with weight loss and a violaceous, cutaneous lesion of the scapula that grew from 3 cm to 30 cm in 5 months. What is your diagnosis?
This Viewpoint describes the barriers to accessing beneficial palliative care under the current Medicare reimbursement structure for hospice.
This Viewpoint explains the importance of patient-reported outcome measures and suggests questions that physicians should ask when determining which set of patient-reported outcome measures to use for an individual patient.
This Viewpoint describes the current anticancer drug–pricing strategy and advocates for a change to a socially owned model.
This JAMA Patient Page describes cancer-related information and groups available online and explains how to determine whether these sources of information are trustworthy.
This essay describes a medical physicist’s interaction with a patient and the profound effect that even the smallest patient interactions can have on health care professionals.
Create a personal account or sign in to: